IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
29.15
-0.32 (-1.09%)
Jun 1, 2026, 1:44 PM EDT - Market open
IDEAYA Biosciences Employees
IDEAYA Biosciences had 145 employees as of December 31, 2025. The number of employees increased by 14 or 10.69% compared to the previous year.
Employees
145
Change (1Y)
14
Growth (1Y)
10.69%
Revenue / Employee
$1,553,586
Profits / Employee
-$965,924
Market Cap
2.56B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 145 | 14 | 10.69% | 145 | 0 |
| Dec 31, 2024 | 131 | 7 | 5.65% | 131 | 0 |
| Dec 31, 2023 | 124 | 21 | 20.39% | 124 | 0 |
| Sep 30, 2023 | 122 | 27 | 28.42% | 122 | 0 |
| Jun 30, 2023 | 116 | 25 | 27.47% | 116 | 0 |
| Mar 31, 2023 | 107 | 20 | 22.99% | 107 | 0 |
| Dec 31, 2022 | 103 | 22 | 27.16% | 103 | 0 |
| Sep 30, 2022 | 95 | 12 | 14.46% | 95 | 0 |
| Jun 30, 2022 | 91 | 16 | 21.33% | 91 | 0 |
| Mar 31, 2022 | 87 | 18 | 26.09% | 87 | 0 |
| Dec 31, 2021 | 81 | 19 | 30.65% | 81 | 0 |
| Sep 30, 2021 | 83 | 25 | 43.10% | 83 | 0 |
| Jun 30, 2021 | 75 | 29 | 63.04% | 75 | 0 |
| Mar 31, 2021 | 69 | 26 | 60.47% | 69 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Vera Therapeutics | 339 |
| Alumis | 227 |
| Structure Therapeutics | 220 |
| Immunome | 206 |
| Celldex Therapeutics | 198 |
| Disc Medicine | 154 |
IDYA News
- 2 hours ago - IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO - PRNewsWire
- 3 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 5 days ago - Ideaya Biosciences management to meet with Cantor - TheFly
- 6 days ago - IDEAYA Biosciences Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 6 days ago - IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference - PRNewsWire
- 13 days ago - IDEAYA Biosciences Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 19 days ago - IDEAYA Biosciences Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 25 days ago - Ideaya Biosciences price target lowered to $50 from $52 at Mizuho - TheFly